Angelman SyndromeNCT06115109
Angelman Natural History Study - FAST Spain
An observational study of Angelman Syndrome, run by Puerta de Hierro University Hospital at 2 sites in Spain.
Trial summary
The goal of this study is to conduct a prospective, longitudinal study to observe the natural clinical progression and disease outcome of AS patients receiving no disease-modified intervention, with the purpose of obtaining data that will be useful for future clinical trials. Read more about this study
- Who is it for?
- Ages 3 months to 99 years
- Conditions the study is for
- Angelman Syndrome
- What is being tested?
- Non intervention, Observational study
- How many people
- 40 participants
- Where
- 2 sitesSpain
- Study dates
- 1 Dec 2023to 1 Jul 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 3 months to 99 years
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: All individuals with a molecular diagnosis of Angelman syndrome
Who may be able to join
- Male or female between 3 months and 99 years of age.
- Clinical diagnosis of Angelman Syndrome and molecular confirmation of the diagnosis.
- The participant has an acceptable guardian capable of giving consent on behalf of the participant,
- Willingness and ability of their guardians to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
Who cannot join
- Patients with any comorbidity that, in the clinical judgment of the principal investigator, may affect the results of the study. Any confirmed chronic or acute condition or illness affecting any system(s) that could interfere with study results and/or compliance with study procedures is included.
- Patients who are participating in parallel studies with investigational drugs.
- Unwillingness or inability of their guardians to follow the procedures outlined in the protocol.
Trial locations and contacts
2 sites in 1 country.
Spain2 sites, 2 recruiting
- Recruiting
Hospital Parc Tauli. Servicio de Genética molecular
Barcelona, 08208
Neus Baena Diez, (+34) 93 6933200, NBaena@tauli.cat
Ariadna Ramírez Mallafré, MD, Ph
- Recruiting
Servicio de Farmacología Clínica. Hospital Universitario Puerta de Hierro Majadahonda
Madrid, 28049
Belen Ruiz Antorán, MD, Ph, (+34) 91 1917479, bruizantoran@gmail.com
M Rosario Cazorla Calleja, MD
About this study
Official title: Observational Study, Prospective Multicentric, From the Natural History of Patients With Angelman Syndrome in Spain
The goal of this study is to conduct a prospective, longitudinal study to observe the natural clinical progression and disease outcome of AS patients receiving no disease-modified intervention, with the purpose of obtaining data that will be useful for future clinical trials.
Read the detailed description
The overall goal is to increase our understanding of the long-term natural history of Angelman syndrome and to identify and validate objective and sensitive outcome measures, which could serve as endpoints for outcome measures that can be used in clinical trials.
- Conditions
- Angelman Syndrome
- Being tested
- Non intervention, Observational study
- Medical subject headings
- Angelman Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Non intervention, Observational studyOther
Non intervention, Observational study
What is being measured
The primary outcome is the main question the study is designed to answer.
Clinical Global Impression Scale for AS (CGI-AS)
Medical and neurological evaluation:
-Clinical Global Impression Scale for AS (CGI-AS). The scale consists of several categories, from "not assessed" to "extremely severe." Professionals assess various aspects of behavior, communication, and the individual's overall functioning to assign a score on the CGI-AS scale. A higher score indicates a greater severity of symptoms, while a lower score indicates less severity.
Measured: 2 years
Hammersmith Neonatal Neurological Examination (HINE) (for 0-2 years)
Medical and neurological evaluation:
Hammersmith Neonatal Neurological Examination (HINE). 26 items that assess neurological function (cranial nerve function, posture, movements, tone, reflexes, and reactions). For neurological function, each item is individually scored on a scale of 0 to 3 based on descriptions and illustrative diagrams, so the total score can range from a minimum of 0 to a maximum of 78.
Measured: 2 years
Secondary outcomes (12)
Movement through actimetry
Continuous monitoring of movement through actimetry. Actigraphs will we placed on the non-dominant wrist or ankle of each participant. The motionlogger measures long-term gross motor activity and integrates degree and intensity of motion, and contains an accelerometer capable of sensing any motion with minimal resultant force of .01g. Actigraphy measurements will we recorded by the motionlogger every second using the proportional integrating measurement (PIM) mode of operation. In PIM mode, a numeric scale of movement activity is provided based on the absolute value of the area under the sensor curve. The PIM data can range from zero, corresponding to no movement when the limb is at rest, to a maximum value of 32,000, corresponding to the most vigorous and extreme movement of the limb.
Measured: 2 years
Motor function scales
Motor function scales:
- Functional Mobility Scale (FMS). The FMS classifies the functional mobility of children 4-18 years of age taking into account the assistive devices a child might use.
3 items (distances), each of which is rated from 1-6 depending on assistance required, or "C" for crawling or "N" if distance is not completed Maximum score is a 6 for each of the distances (5m, 50m, and 500m)
Measured: 2 years
Global development: Bayley Scale-3 (BSID-3)
-Bayley Scale-3 (BSID-3), at the time that version 4 of the Bayley scale (BSID-4) is validated in Spanish, it will be used in the context of the registry.
Bayley Scales of Infant Development III, cognitive scale; raw scores used to reflect change over time and absolute growth (rather than standard scores) Range: Minimum =20 points; Maximum=60 Higher score = better outcome
Measured: 2 years
Global development: Vineland Scale-III (VABS-III)
Vineland Scale-III is designed to measure adaptive behavior of individuals from birth to age 90. The Vineland-II contains 5 domains each with 2-3 subdomains. The main domains are: Communication, Daily Living Skills, Socialization, Motor Skills, and Maladaptive Behavior.
Measured: 2 years
Global development: Aberrant behavior scale (ABC-C)
Aberrant behavior scale (ABC-C). The ABC-C is a global behavior checklist that measures drug and other treatment effects in people with developmental disabilities. It is made up of five subscales, including Irritability, Lethargy, Inappropriate Speech, Hyperactivity, and Stereotypy based on 58 items that describe various behavioral problems.
Measured: 2 years
Communication assessment: ORCA communication tool (specifically designed for patients with AS)
ORCA communication tool (specifically designed for patients with AS). Observed Reported Communication Assessment (ORCA) Tool. Questionnaire designed to be completed by the patients' main carer and records patient communication.
Measured: 2 years
Communication assessment: Leiter-3, Nonverbal Intelligence Scale
-Leiter-3, Nonverbal Intelligence Scale (for patients with equivalent developmental age greater than 3 years 6 months). Is a totally nonverbal test of intelligence and cognitive abilities. Evaluates nonverbal cognitive, attentional, and neuropsychological abilities, and targets 'typical' as well as 'atypical' children, adolescents, and now adults.
Measured: 2 years
Sleep Disorders: Childhood Sleep Disorders Scale (Bruni Scale)
-Childhood Sleep Disorders Scale (Bruni Scale). The SDSC is a 26-item scale developed to assess the presence of sleep difficulties in children within the previous six months.
Divided items into six categories representing some of the most common sleep diffi culties affecting adolescents and children: disorders of initiating and maintaining sleep, sleep breathing disorders, disorders of arousal/nightmares, sleep-wake transition disorders, disorders of excessive somnolence, and sleep hyperhidrosis (nighttime sweating).
The measure is completed by the parent of the child and takes approximately 5-10 min to complete. Item 1 measures the child's average hours of sleep, from 1 ('9 - 11 h') to 5 ('less than 5 h'). Item 2 measures the child's average time to fall asleep, from 1 ('less than 15 min') to 5 ('more than 60 min'). The remaining 24 items are rated on a 5-point Likert scale, from 1 ('Never') to 5 ('Always [daily]').
Measured: 2 years
Sleep Disorders: Children's Sleep Habits Questionnaire (CSHQ)
-Children's Sleep Habits Questionnaire (CSHQ) This questionnaire was designed as a sleep screening instrument for school-aged children that yields final scores across eight subscales: bedtime resistance, sleep resistance, parasomnia, sleep disordered breathing, night-wakings, daytime sleepiness, sleep anxiety, and sleep onset delay, as well as a summative score, called the Total Sleep Disturbance score.
Measured: 2 years
Sleep Disorders: Diaries
This study will utilize a brief 6-item sleep diary to collect parent-reported sleep variables (e.g., "what time was your child down for the night?").
Measured: 2 years
Proteomic analysis
Proteomic analysis: Ubiquitin proteomics approach. Characterization of ubiquitination by Ube3a, a proteasomal component conserved from yeast (Ddi1) to humans (DDI1 and DDI2).
Measured: 2 years
Electroencephalogram (EEG) activity recordings
Electroencephalogram (EEG) to record brain activity of Angelman Syndrome patients over a 4-hour period (e.g., sleep architecture, number and frequency of seizures, background epileptic activity, delta-rhythmicity)
Measured: 2 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Nov 2023
- Study start1 Dec 2023
- Primary completion31 Dec 2024 (estimated)
- Study completion1 Jul 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Angelman SyndromeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Puerta de Hierro University Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- Parc Taulí Hospital Universitari
- Responsible party
- Principal investigator, BELEN RUIZ-ANTORAN, Puerta de Hierro University Hospital
- Investigators
- BELEN RUIZ ANTORAN, MD, Ph, Principal investigator, Clinical Pharmacology Deparment, Hospital Universitario Puerta de Hierro Majadahonda
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06115109
- Sponsor's protocol ID
- 01_FAST SPAIN
- Status last verified
- Apr 2024
- First submitted
- 26 Jul 2022
- Last updated
- 3 Apr 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 3 Apr 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Observational Study, Prospective Multicentric, From the Natural History of Patients With Angelman Syndrome in Spain
- ClinicalTrials.gov ID
- NCT06115109
- Acronym / sponsor ID
- 01_FAST SPAIN
- Conditions
- Angelman Syndrome
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 40 participants (estimated)
- Lead sponsor
- Puerta de Hierro University HospitalUniversity, hospital or other
- Collaborators
- Parc Taulí Hospital Universitari
- Study start
- 1 Dec 2023 (actual)
- Primary completion
- 31 Dec 2024 (estimated)
- Study completion
- 1 Jul 2025 (estimated)
- First posted
- 2 Nov 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this study is to conduct a prospective, longitudinal study to observe the natural clinical progression and disease outcome of AS patients receiving no disease-modified intervention, with the purpose of obtaining data that will be useful for future clinical trials.
Detailed description
The overall goal is to increase our understanding of the long-term natural history of Angelman syndrome and to identify and validate objective and sensitive outcome measures, which could serve as endpoints for outcome measures that can be used in clinical trials.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 3 months to 99 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- All individuals with a molecular diagnosis of Angelman syndrome
Key inclusion criteria (4 listed)
- Male or female between 3 months and 99 years of age.
- Clinical diagnosis of Angelman Syndrome and molecular confirmation of the diagnosis.
- The participant has an acceptable guardian capable of giving consent on behalf of the participant,
- Willingness and ability of their guardians to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
Key exclusion criteria (3 listed)
- Patients with any comorbidity that, in the clinical judgment of the principal investigator, may affect the results of the study. Any confirmed chronic or acute condition or illness affecting any system(s) that could interfere with study results and/or compliance with study procedures is included.
- Patients who are participating in parallel studies with investigational drugs.
- Unwillingness or inability of their guardians to follow the procedures outlined in the protocol.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Non intervention, Observational studyNon intervention, Observational study | Other | – |
Primary outcome
Clinical Global Impression Scale for AS (CGI-AS)
Time frame: 2 years
Medical and neurological evaluation: -Clinical Global Impression Scale for AS (CGI-AS). The scale consists of several categories, from "not assessed" to "extremely severe." Professionals assess various aspects of behavior, communication, and the individual's overall functioning to assign a score on the CGI-AS scale. A higher score indicates a greater severity of symptoms, while a lower score indicates less severity.
Hammersmith Neonatal Neurological Examination (HINE) (for 0-2 years)
Time frame: 2 years
Medical and neurological evaluation: Hammersmith Neonatal Neurological Examination (HINE). 26 items that assess neurological function (cranial nerve function, posture, movements, tone, reflexes, and reactions). For neurological function, each item is individually scored on a scale of 0 to 3 based on descriptions and illustrative diagrams, so the total score can range from a minimum of 0 to a maximum of 78.
12 secondary outcomes
Movement through actimetry
Time frame: 2 years
Motor function scales
Time frame: 2 years
Global development: Bayley Scale-3 (BSID-3)
Time frame: 2 years
Global development: Vineland Scale-III (VABS-III)
Time frame: 2 years
Global development: Aberrant behavior scale (ABC-C)
Time frame: 2 years
Communication assessment: ORCA communication tool (specifically designed for patients with AS)
Time frame: 2 years
Communication assessment: Leiter-3, Nonverbal Intelligence Scale
Time frame: 2 years
Sleep Disorders: Childhood Sleep Disorders Scale (Bruni Scale)
Time frame: 2 years
Sleep Disorders: Children's Sleep Habits Questionnaire (CSHQ)
Time frame: 2 years
Sleep Disorders: Diaries
Time frame: 2 years
Proteomic analysis
Time frame: 2 years
Electroencephalogram (EEG) activity recordings
Time frame: 2 years
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Apr 2024.
- Individual participant dataSharing planned: Undecided
Related trials for Angelman Syndrome
RecruitingPhase 3
BEACON - Phase III Clinical Study of Rugonersen in Angelman Syndrome.
Angelman Syndrome
RecruitingPhase 3
CHAMPION: A Study to Evaluate the Efficacy and Safety of Obudanersen (ION582) in Children and Adults With Angelman Syndrome (AS)
Angelman Syndrome
RecruitingObservational study
A Natural History Study of Angelman Syndrome
Angelman Syndrome, Neurodevelopmental Conditions
Active, not recruitingPhase 3
REVEAL: A Phase 3 Study of Obudanersen (ION582) in Angelman Syndrome
Angelman Syndrome
Active, not recruiting
Web Intervention for Parents of Youth With Genetic Syndromes (WINGS)
Telomeric 22Q13 Monosomy Syndrome, Tuberous Sclerosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
BELEN RUIZ ANTORAN, MD, Ph principal investigator
Clinical Pharmacology Deparment, Hospital Universitario Puerta de Hierro Majadahonda
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Angelman Syndrome, run by Puerta de Hierro University Hospital at 2 sites in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 3 Apr 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact BELEN RUIZ ANTORAN, MD, Ph (+34911917479, bruizantoran@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Clinical Global Impression Scale for AS (CGI-AS) (time frame: 2 years). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Apr 2024.